YILI(SH:600887) Zhong Guo Zhi Liang Xin Wen Wang·2026-02-11 07:13Core Insights - YLGB-1496, a probiotic strain developed by Yili, has been included in the list of probiotics approved for infant food by the National Health Commission of China, marking a significant breakthrough in the domestic probiotic industry [1][5] Group 1: Probiotic Development - YLGB-1496 is the first probiotic strain in the list that is independently developed by a Chinese dairy company and derived from Chinese breast milk [1][5] - The strain is designed to be more compatible with the physical needs of Chinese infants, providing a tailored probiotic solution [1][4] Group 2: Health Benefits - Clinical studies conducted in collaboration with the National Dairy Technology Innovation Center have shown that YLGB-1496 significantly reduces the incidence of eczema and respiratory infections in infants, aiding in the development of their immune systems [5] - The strain has also been proven to enhance gut comfort in infants, reducing the occurrence and severity of diarrhea [5] Group 3: Industrialization and Product Application - Yili's subsidiary, Jinqi Biotechnology, is responsible for the industrialization and commercialization of YLGB-1496, ensuring high-quality and diverse probiotic products for the health food industry [6] - The strain has already been incorporated into several products, including QQ Star's maternal care products and mixed fruit and vegetable juices, with plans for further applications in infant formula [6] Group 4: Future Prospects - The approval of YLGB-1496 signifies a major leap for the Chinese dairy industry from technology following to independent innovation in the probiotic sector [7] - Yili aims to continue its research on the functional properties of the strain and promote the transformation of scientific achievements into products, contributing to the high-quality development of the Chinese dairy industry [7]